Abstract
(1) The treatment of choice for Parkinson’s disease (PD) is 3,4-dihydroxyphenylalanine (L-DOPA) with peripheral decarboxylase inhibitor, but long-term therapy leads to motor and psychiatric complications. In the present study we investigated 5-hydroxytryptamine (5-HT) and dopamine concentrations in serotonergic and dopaminergic nuclei following chronic administration of L-DOPA to find whether the neurotransmitter synthesis in these brain areas are compensated. (2) Rats were administered L-DOPA (250 mg/kg) and carbidopa (25 mg/kg) daily for 59 and 60 days, and killed on the 60th day, respectively at 24 h and 30 min after the last dose. L-DOPA, norepinephrine, 5-HT, 5-hydroxyindoleacetic acid (5-HIAA), dopamine, homovanillic acid (HVA), and 3,4-dihydroxyphenylacetic acid (DOPAC) were measured in striatum, nucleus raphe dorsalis (NRD), nucleus accumbens (NAc), substantia nigra, cerebellum, and cortex employing HPLC-electrochemical procedure. (3) Prolonged treatment of L-DOPA caused depression in the animals as revealed in a forced swim test. Serotonin content was significantly decreased in all brain regions studied 30 min after long-term L-DOPA, except in NAc. The cortex and striatum showed lowered levels of this indoleamine 24 h after 59 doses of L-DOPA. Dopamine, HVA, and DOPAC concentrations were significantly higher in all the regions studied after 30 min, and in the cerebellum after 24 h of L-DOPA. The levels of DOPAC were elevated in all the brain areas studied 24 h after prolonged L-DOPA treatment. (4) The present results suggest that long-term L-DOPA treatment results in significant loss of 5-HT in serotonergic and dopaminergic regions of the brain. Furthermore, while L-DOPA metabolism per se was uninfluenced, dopamine synthesis was severely impaired in all the regions. The imbalance of serotonin and dopamine formation may be the cause of overt cognitive, motor, and psychological functional aberrations seen in parkinsonian patients following prolonged L-DOPA treatment.
Similar content being viewed by others
References
Adell A, Celada P, Artigas F (2001) The role of 5-HT1B receptors in the regulation of serotonin cell firing and release in the rat brain. J Neurochem 79:172–182
Ahlskog JE, Muenter MD (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16:448–458
Arai R, Karasawa N, Geffard M, Nagatsu T, Nagatsu I (1994) Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenous L-DOPA in the rat, with reference to the involvement of aromatic L-amino acid decarboxylase. Brain Res 667:295–299
Arai R, Karasawa N, Geffard M, Nagatsu I (1995) L-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat. A double-labeling immunofluorescence study. Neurosci Lett 195:195–198
Arai R, Karasawa N, Nagatsu I (1996) Aromatic l-amino acid decarboxylase is present in serotonergic fibers of the striatum of the rat. A double-labeling immunofluorescence study. Brain Res 706:177–179
Bishop C, Taylor JL, Kuhn DM, Eskow KL, Park JY, Walker PD (2006) MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation. Eur J Neurosci 23:2669–2676
Brown WD, Taylor MD, Roberts AD, Oakes TR, Schueller MJ, Holden JE, Malischke LM, DeJesus OT, Nickles RJ (1999) Fluorodopa PET shows the nondopaminergic as well as dopaminergic destinations of levodopa. Neurology 53:1212–1218
Carlsson A (1993) Thirty years of dopamine research. Adv Neurol 60:1–10
Cenci MA (2007) Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci 30:236–243
Chandra G, Gangopadhyay PK, Senthil Kumar KS, Mohanakumar KP (2006) Acute intranigral homocysteine administration produces stereotypic behavioral changes and striatal dopamine depletion in Sprague–Dawley rats. Brain Res 1075:81–92
Chase TN (1998) Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology 50:S17–S25
Chesselet MF, Delfs JM (1996) Basal ganglia and movement disorders: an update. Trends Neurosci 19:417–422
Christenson JG, Dairman W, Udenfriend S (1970) Preparation and properties of a homogeneous aromatic L-amino acid decarboxylase from hog kidney. Arch Biochem Biophys 141:356–367
Cummings JL, Masterman DL (1999) Depression in patients with Parkinson’s disease. Int J Geriatr Psychiatry 14:711–718
Guerra MJ, Liste I, Labandeira-Garcia JL (1998) Interaction between the serotonergic, dopaminergic, and glutamatergic systems in fenfluramine-induced Fos expression in striatal neurons. Synapse 28:71–82
Hefti F, Melamed E, Wurtman RJ (1981) The site of dopamine formation in rat striatum after l-DOPA administration. J Pharmacol Exp Ther 217:189–197
Hornykiewicz O (1998) Biochemical aspects of Parkinson’s disease. Neurology 51:S2–S9
Hui JS, Murdock GA, Chung JS, Lew MF (2005) Behavioral changes as side effects of medication treatment for Parkinson’s disease. Adv Neurol 96:114–129
Jaeger CB, Teitelman G, Joh TH, Albert VR, Park DH, Reis DJ (1983) Some neurons of the rat central nervous system contain aromatic L-amino acid decarboxylase but not monoamines. Science 219:1233–1235
Kannari K, Tanaka H, Maeda T, Tomiyama M, Suda T, Matsunaga M (2000) Reserpine pretreatment prevents increases in extracellular striatal dopamine following l-DOPA administration in rats with nigrostriatal denervation. J Neurochem 74:263–269
Kannari K, Shen H, Arai A, Tomiyama M, Baba M (2006) Reuptake of l-DOPA-derived extracellular dopamine in the striatum with dopaminergic denervation via serotonin transporters. Neurosci Lett 402:62–65
Klapdor K, Dulfer BG, Hammann A, Van der Staay FJ (1997) A low-cost method to analyse footprint patterns. J Neurosci Methods 75:49–54
Knobelman DA, Kung HF, Lucki I (2000) Regulation of extracellular concentrations of 5-hydroxytryptamine (5-HT) in mouse striatum by 5-HT1A and 5-HT1B receptors. J Pharmacol Exp Ther 292:1111–1117
Kostic VS, Djuricic BM, Covickovic-Sternic N, Bumbasirevic L, Nikolic M, Mrsulja BB (1987) Depression and Parkinson’s disease: possible role of serotonergic mechanisms. J Neurol 234:94–96
Lavoie B, Parent A (1990) Immunohistochemical study of the serotoninergic innervation of the basal ganglia in the squirrel monkey. J Comp Neurol 299:1–16
Leentjens AF (2004) Depression in Parkinson’s disease: conceptual issues and clinical challenges. J Geriatr Psychiatry Neurol 17:120–126
Lemke MR, Fuchs G, Gemende I, Herting B, Oehlwein C, Reichmann H, Reike J, Volkmann J (2004) Depression and Parkinson’s disease. J Neurol 6:24–27
Lopez A, Munoz A, Guerra MJ, Labandeira-Garcia JL (2001) Mechanisms of the effects of exogenous levodopa on the dopamine denervated-striatum. Neuroscience 103:639–651
Lovenberg W, Weissbach H, Udenfriend S (1962) Aromatic L-amino acid decarboxylase. J Biol Chem 237:89–93
Maeda T, Nagata K, Yoshida Y, Kannari K (2005) Serotonergic hyperinnervation into the dopaminergic-denervated striatum compensates for dopamine conversion from exogenously administered l-DOPA. Brain Res 1046:230–233
Mazzella L, Yahr MD, Marinelli L, Huang N, Moshier E, Di Rocco A (2005) Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson’s disease on l-DOPA monotherapy. Parkinsonism Relat Disord 11:151–155
Mehta H, Saravanan KS, Mohanakumar KP (2003) Serotonin synthesis inhibition in olivo-cerebellar system attenuates harmaline-induced tremor in Swiss albino mice. Behav Brain Res 145:31–36
Meissner W, Ravenscroft P, Reese R, Harnack D, Morgenstern R, Kupsch A, Klitgaard H, Bioulac B, Gross CE, Bezard E, Boraud T (2006) Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine. Neurobiol Dis 22:586–598
Miller D, Abercrombie ED (1999) Role of high-affinity dopamine uptake and impulse activity in the appearance of extracellular dopamine in striatum after administration of exogenous L-DOPA: studies in intact and 6-hydroxydopamine-treated rats. J Neurochem 72:1516–1522
Mura A, Jackson D, Manley MS, Young SJ, Groves PM (1995) Aromatic L-amino acid decarboxylase immunoreactive cells in the rat striatum: a possible site for the conversion of exogenous L-DOPA to dopamine. Brain Res 704:51–60
Muralikrishnan D, Mohanakumar KP (1998) Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. FASEB J 12:905–912
Nicholson SL, Brotchie JM (2002) 5-hydroxytryptamine (5-HT, serotonin) and Parkinson’s disease—opportunities for novel therapeutics to reduce the problems of levodopa therapy. Eur J Neurol 9:1–6
Nutt JG (1990) Levodopa-induced dyskinesia: review, observations, and speculations. Neurology 40:340–345
Palkovits M, Brownstein MJ (1983) Brain microdissection techniques. John Wiley and Sons, New York
Poewe W (2003) Psychosis in Parkinson’s disease. Mov Disord 6:S80–S87
Porsolt RD, Pichon LM, Jalfre M (1977) Depression: a new animal model sensitive to antidepressant treatments. Nature 266:730–732
Rozas G, Liste I, Guerra MJ, Labandeira-Garcia JL (1998) Sprouting of the serotonergic afferents into striatum after selective lesion of the dopaminergic system by MPTP in adult mice. Neurosci Lett 245:151–154
Steinbusch HWM (1984) Serotonin-immunoreactive neurons and their projections in the CNS. In: Bjorklund A, Hokfelt T, Kuhar MJ (eds) Handbook of chemical neuroanatomy, vol. 3, classical transmitter receptors in the CNS, part II. Elsevier Sciences Publishers, Amsterdam, pp. 68–125
Acknowledgment
Anupom Borah is a recipient of Senior Research Fellowship from the Council of Scientific and Industrial Research, Government of India.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Borah, A., Mohanakumar, K.P. Long-Term L-DOPA Treatment Causes Indiscriminate Increase in Dopamine Levels at the Cost of Serotonin Synthesis in Discrete Brain Regions of Rats. Cell Mol Neurobiol 27, 985–996 (2007). https://doi.org/10.1007/s10571-007-9213-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10571-007-9213-6